1. Home
  2. NWS vs INCY Comparison

NWS vs INCY Comparison

Compare NWS & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo News Corporation Class B

NWS

News Corporation Class B

SELL

Current Price

$32.45

Market Cap

17.9B

ML Signal

SELL

Logo Incyte Corp.

INCY

Incyte Corp.

SELL

Current Price

$111.71

Market Cap

17.0B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
NWS
INCY
Founded
2012
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Biotechnology: Commercial Physical & Biological Resarch
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.9B
17.0B
IPO Year
2012
1994

Fundamental Metrics

Financial Performance
Metric
NWS
INCY
Price
$32.45
$111.71
Analyst Decision
Buy
Analyst Count
0
28
Target Price
N/A
★ $129.13
AVG Volume (30 Days)
1.0M
★ 1.6M
Earning Date
11-05-2026
10-29-2026
Dividend Yield
★ 0.62%
N/A
EPS Growth
N/A
★ 4173.33
EPS
1.03
★ 1.47
Revenue
★ $9,028,000,000.00
$3,394,635,000.00
Revenue This Year
$4.24
$15.49
Revenue Next Year
$3.48
$5.35
P/E Ratio
★ $31.04
$76.76
Revenue Growth
6.81
★ 13.67
52 Week Low
$25.49
$83.50
52 Week High
$35.76
$132.60

Technical Indicators

Market Signals
Indicator
NWS
INCY
Relative Strength Index (RSI) 51.27 29.48
Support Level $29.48 $110.56
Resistance Level $32.91 $119.29
Average True Range (ATR) 0.66 3.13
MACD 0.07 -1.15
Stochastic Oscillator 94.18 7.20

Price Performance

Historical Comparison
NWS
INCY

About NWS News Corporation Class B

News Corporation is a diversified media and information services conglomerate with significant presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings platform in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: